Product Information
ACAMPROSATE CALC DR 333 MG TAB is a generic product labeled by Bionpharma Inc., priced at $0.5891 per EA under NDC 69452035325. Its NADAC has been published 38 times since Jan 14, 2026.
FDA first approved this application on Sep 18, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
333 mg/1
Manufacturer
Bionpharma Inc.NDC
69452035325
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACAMPROSATE CALCIUMApproval Type
Generic (ANDA)
FDA Application
ANDA219904FDA Approved
9/18/2025
TE Code
AB
On Market Since
12/1/2025
Price Statistics
The NADAC for ACAMPROSATE CALC DR 333 MG TAB has been published 38 times since Jan 14, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5891 per EA |
|---|---|
| All-time high | $0.6218 (Feb 11, 2026) |
| All-time low | $0.5871 (May 20, 2026) |
| 52-week high | $0.6218 |
| 52-week low | $0.5871 |
| Median price | $0.6086 |
| Average price | $0.6076 |
| Largest weekly change | +4.0% (Jan 21, 2026) |
| Weeks tracked | 38 |
| Tracking since | Jan 14, 2026 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acamprosate Calcium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACAMPROSATE CALC DR 333 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ACAMPROSATE CALC DR 333 MG TAB, manufactured by Bionpharma Inc., is $0.5891 per EA (NDC 69452035325), effective Sep 30, 2026.
How has the price of ACAMPROSATE CALC DR 333 MG TAB changed over time?
Over the history we have for it, the NADAC for ACAMPROSATE CALC DR 333 MG TAB has held within roughly two percent of its current level. It has been tracked across 38 weekly CMS publications since Jan 14, 2026.
What are the highest and lowest recorded NADAC prices for ACAMPROSATE CALC DR 333 MG TAB?
Since Jan 14, 2026, the NADAC for ACAMPROSATE CALC DR 333 MG TAB has ranged from a low of $0.5871 (May 20, 2026) to a high of $0.6218 (Feb 11, 2026), with a median of $0.6086 per EA.
Are there cheaper alternatives to ACAMPROSATE CALC DR 333 MG TAB?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ACAMPROSATE CALC DR 333 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures ACAMPROSATE CALC DR 333 MG TAB?
ACAMPROSATE CALC DR 333 MG TAB (NDC 69452035325) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.